AACR 2023 Conference Coverage
First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor of YAP/TEAD, in Pts With Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors With NF2 Mutations
By
AACR 2023 Conference Coverage
FEATURING
Timothy Yap
By
AACR 2023 Conference Coverage
FEATURING
Timothy Yap
Comments 0
Login to view comments.
Click here to Login
